6:00 pm Prosensa Holding announces 48-week data from U.S. Phase 2 study of drisapersen in 51 DMD boys: Clinically meaningful improvement from 24-week treatment period was maintained for 24 weeks after drisapersen administration ceased – HedgeChatter

6:00 pm Prosensa Holding announces 48-week data from U.S. Phase 2 study of drisapersen in 51 DMD boys: Clinically meaningful improvement from 24-week treatment period was maintained for 24 weeks after drisapersen administration ceased

18 Mar

6:00 pm Prosensa Holding announces 48-week data from U.S. Phase 2 study of drisapersen in 51 DMD boys: Clinically meaningful improvement from 24-week treatment period was maintained for 24 weeks after drisapersen administration ceased

Bystocknews RNA, stock Comments Off

View todays social media effects on RNA

View the latest stocks trending across Twitter. Click to view dashboard

See who Prosensa is hiring next, click here to view

Author